MedTrace Logo

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

NCT07056777 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2026-01-13

No results posted yet for this study

Summary

This is a multicenter, open-label phase Ib/IIa clinical study conducted in China, aimed at evaluating the safety tolerance, efficacy, pharmacokinetic (PK) characteristics, and immunogenicity of DR30206 in combination with standard treatment regimens for advanced or metastatic gastrointestinal tumors.

Conditions

Interventions

DRUG

DR30206

Subjects receive DR30206 intravenously

DRUG

Oxaliplatin

Subjects receive Oxaliplatin intravenously

DRUG

Capecitabine

Subjects take Capecitabine orally

DRUG

Calcium Folinate

Subjects receive Calcium Folinate intravenously

DRUG

5-FU

Subjects receive 5-FU by Intravenous Bolus

DRUG

Irinotecan (CPT-11)

Subjects receive Irinotecan intravenously

Sponsors & Collaborators

  • Zhejiang Doer Biologics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yanshan Huang CEO · Zhejiang Doer Biologics Co., Ltd.

  • Ruihua Xu · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-25
Primary Completion
2026-04-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07056777 on ClinicalTrials.gov